MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 526514 | Name: Troxipide
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Troxipide is a drug used in the treatment of gastroesophageal reflux disease. Troxipide is a novel systemic non-antisecretory gastric cytoprotective agent with anti-ulcer, anti-inflammatory and mucus secreting properties irrespective of pH of stomach or duodenum. The unique gastric pH and content independent properties of troxipide include the following: Gastric mucosal protection, Stimulation of cytoprotective prostaglandins, Suppression of gastric inflammation, Enhancement of mucosal metabolism, Stimulation of mucosal microcirculation, and Anti-Helicobacter pylori action.

Chemical Structure

Troxipide
Troxipide
CAS#30751-05-4

Theoretical Analysis

MedKoo Cat#: 526514

Name: Troxipide

CAS#: 30751-05-4

Chemical Formula: C15H22N2O4

Exact Mass: 294.1580

Molecular Weight: 294.35

Elemental Analysis: C, 61.21; H, 7.53; N, 9.52; O, 21.74

Price and Availability

Size Price Availability Quantity
500mg USD 150.00
1g USD 250.00
2g USD 450.00
5g USD 850.00
10g USD 1,450.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
BRN0493078; BRN-0493078; BRN 0493078; Troxipide; Troxipida; Troxipidum
IUPAC/Chemical Name
3,4,5-trimethoxy-N-(piperidin-3-yl)benzamide
InChi Key
YSIITVVESCNIPR-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H22N2O4/c1-19-12-7-10(8-13(20-2)14(12)21-3)15(18)17-11-5-4-6-16-9-11/h7-8,11,16H,4-6,9H2,1-3H3,(H,17,18)
SMILES Code
O=C(NC1CNCCC1)C2=CC(OC)=C(OC)C(OC)=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 294.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Gao Y, Gao Y, Yin F, Wang M, Wang Z, Ye T, Yang Y, Pan WS, Yang X. Preparation and pharmacokinetics study on gastro-floating sustained-release tablets of troxipide. Drug Dev Ind Pharm. 2015;41(9):1443-51. doi: 10.3109/03639045.2014.956113. Epub 2015 Jul 21. PubMed PMID: 25190152. 2: Jagdale SC, Kamble SB, Kuchekar BS, Chabukswar AR. Design and evaluation of polyox and pluronic controlled gastroretentive delivery of troxipide. J Drug Deliv. 2014;2014:804616. doi: 10.1155/2014/804616. Epub 2014 Nov 19. PubMed PMID: 25505995; PubMed Central PMCID: PMC4253710. 3: Dewan B, Balasubramanian A. Troxipide in the management of gastritis: a randomized comparative trial in general practice. Gastroenterol Res Pract. 2010;2010:758397. doi: 10.1155/2010/758397. Epub 2010 Nov 25. PubMed PMID: 21127703; PubMed Central PMCID: PMC2992815. 4: Kusugami K, Ina K, Hosokawa T, Kobayashi F, Kusajima H, Momo K, Nishio Y. Troxipide, a novel antiulcer compound, has inhibitory effects on human neutrophil migration and activation induced by various stimulants. Dig Liver Dis. 2000 May;32(4):305-11. PubMed PMID: 11515628. 5: Momo K, Hoshina K, Ishibashi Y, Saito T. [Preventive effects of troxipide on a newly developed model of acute gastric mucosal lesion (AGML) induced by ischemia/reperfusion plus ammonia in the rat]. Nihon Yakurigaku Zasshi. 1994 Oct;104(4):313-23. Japanese. PubMed PMID: 7959422. 6: Sekiguchi H, Hamada K, Okada Y, Taga F. [Effects of troxipide on acute gastric lesions in rats]. Nihon Yakurigaku Zasshi. 1987 Mar;89(3):111-9. Japanese. PubMed PMID: 3583134. 7: Wang J, Zhang L, Fang Z, Fan A, Wang Y. [The pharmacodynamics of troxipide on experimental gastric ulcers in rats]. Hua Xi Yi Ke Da Xue Xue Bao. 1993 Sep;24(3):313-6. Chinese. PubMed PMID: 8288208. 8: Onuma W, Tomono S, Miyamoto S, Fujii G, Hamoya T, Fujimoto K, Miyoshi N, Fukai F, Wakabayashi K, Mutoh M. Irsogladine maleate, a gastric mucosal protectant, suppresses intestinal polyp development in Apc-mutant mice. Oncotarget. 2016 Feb 23;7(8):8640-52. doi: 10.18632/oncotarget.7082. PubMed PMID: 26840084. 9: Nakamura M, Endo K, Nakata K, Hamano T. Gefarnate increases PAS positive cell density in rabbit conjunctiva. Br J Ophthalmol. 1998 Nov;82(11):1320-3. PubMed PMID: 9924342; PubMed Central PMCID: PMC1722405. 10: Matsui H, Murata Y, Kobayashi F, Shiba R, Momo K, Kondo Y, Nakahara A, Muto H. Diclofenac-induced gastric mucosal fluorescence in rats. Dig Dis Sci. 2001 Feb;46(2):338-44. PubMed PMID: 11281183. 11: Sekiguchi H, Hamada K, Taga F, Nishino K. Effects of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy]propyl] urea with potent gastric mucosal protective activity on acute gastric lesions and duodenal ulcers in rats. Arzneimittelforschung. 1993 Feb;43(2):134-8. PubMed PMID: 8096133. 12: Irié T, Maeda Y, Aida T, Sumitani K, Nagumo M, Tachikawa T. Multiple granulomatous inflammation in the minor salivary glands: a proposed new entity, allergic granulomatous sialadenitis. Pathol Int. 2004 Nov;54(11):850-3. PubMed PMID: 15533228. 13: Jin M, Otaka M, Watanabe S. [New therapeutic approaches to peptic ulcer using mucosal protective agents]. Nihon Rinsho. 2002 Feb;60 Suppl 2:377-81. Review. Japanese. PubMed PMID: 11979810. 14: Abe Y, Sekiguchi H, Tsuru K, Irikura T. [Effects of 3,4,5-trimethoxy-N-(3-piperidyl) benzamide (KU-54) on the incorporation (excretion) of 14C-glucosamine in the gastric mucosa and the liver of rats]. Nihon Yakurigaku Zasshi. 1984 Jul;84(1):11-8. Japanese. PubMed PMID: 6489865. 15: Abe Y, Sekiguchi H, Tsuru K, Irikura T. [Effects of 3,4,5-trimethoxy-N-(3-piperidyl) benzamide (KU-54) on respiration of the gastric mucosa and liver in rats]. Nihon Yakurigaku Zasshi. 1984 Apr;83(4):317-24. Japanese. PubMed PMID: 6745811. 16: Abe Y, Irikura T. [Influence of 3-(3, 4, 5-trimethoxybenzamido) piperidine (KU-54) on gastric mucosal blood flow (author's transl)]. Nihon Yakurigaku Zasshi. 1980 Sep;76(5):355-61. Japanese. PubMed PMID: 7203276. 17: Nakamura M, Endo K, Nakata K, Hamano T. Gefarnate stimulates secretion of mucin-like glycoproteins by corneal epithelium in vitro and protects corneal epithelium from desiccation in vivo. Exp Eye Res. 1997 Oct;65(4):569-74. PubMed PMID: 9464189. 18: Harada Y, Hara H, Sukamoto T. Receptor binding profiles of KB-5492, a novel anti-ulcer agent, at sigma receptors in guinea-pig brain. Eur J Pharmacol. 1994 May 2;256(3):321-8. PubMed PMID: 8045277. 19: Harada Y, Hara H, Sukamoto T. Binding properties of KB-5492, a novel anti-ulcer agent, at sigma receptors in porcine gastric fundic mucosa. Eur J Pharmacol. 1994 Aug 11;261(1-2):91-6. PubMed PMID: 8001658.